Ironwood Pharmaceuticals Inc
Veridion Score
Composite trend over time
Why is IRWD moving today?
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IRWD.
IRWD insider activity
Ironwood Pharmaceuticals Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$22.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | 2026-03-17 | DENNER ALEXANDER J | Insider | sell | $3.31 | 5,800 | 9,188,635 | $19K | SEC Form 4 |
| 2026-03-17 | 2026-03-17 | DENNER ALEXANDER J | Insider | sell | $3.05 | 6,725,000 | 9,194,435 | $20.5M | SEC Form 4 |
| 2026-02-25 | 2026-02-24 | Martini Gregory S. | Insider | sell | $3.66 | 11,457 | 160,601 | $42K | SEC Form 4 |
| 2026-02-25 | 2026-02-24 | Gaskins Tammi L | Insider | sell | $3.66 | 11,239 | 213,738 | $41K | SEC Form 4 |
| 2026-02-25 | 2026-02-24 | MCCOURT Thomas A | Insider | sell | $3.66 | 103,526 | 1,489,002 | $379K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 15 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moIRWD contract awards, year to date.
Public federal awards linked to this ticker.
IRWD lobbying filings, year to date.
Registered lobbying filings matched to Ironwood Pharmaceuticals Inc.